Kolaric Tea Omanovic, Nincevic Vjera, Kuna Lucija, Duspara Kristina, Bojanic Kristina, Vukadin Sonja, Raguz-Lucic Nikola, Wu George Y, Smolic Martina
University of Osijek, Faculty of Medicine, Osijek, Croatia.
University of Osijek, Faculty of Dental Medicine and Health, Osijek, Croatia.
J Clin Transl Hepatol. 2021 Oct 28;9(5):731-737. doi: 10.14218/JCTH.2020.00091. Epub 2021 Sep 14.
Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.
代谢功能障碍相关脂肪性肝病（通常称为MAFLD）正以流行态势影响着全球健康，其所导致的发病率、死亡率和经济负担都极为巨大。虽然代谢综合征和肥胖作为致病因素已备受关注，但多药联用情况日益增多，尤其是在老年人中，这总体上大大增加了药物性肝损伤（DILI）的风险，特别是药物性脂肪性肝病（DIFLD）的风险。本综述聚焦于DIFLD在流行病学、病理生理学、与DIFLD相关的最常见药物以及治疗策略等方面对DILI的影响。
